Amino Axiom is a free research information and tracking platform that sits alongside the vendor network this brand belongs to. Its compound library is a browsable index of 79 research compounds. Each entry collects three kinds of information in one place: a sourced description of the mechanism studied in the literature, structural data, and a regulatory-status summary. The library is reachable at https://www.aminoaxiom.com/compounds.
This FAQ walks through what those entries show and how a researcher working with small molecules, rather than long peptide chains, can read them. The focus is on the reading process, not on any use of the compounds. Everything here is for research purposes only.
Why does a small-molecule researcher need a compound library at all?
Small-molecule research compounds are easy to mislabel. Names overlap, salt forms differ, and common shorthand ("the AMPK compound", "the NNMT inhibitor") hides the fact that several distinct molecules sit behind each phrase. A library entry gives one stable reference point: a canonical name, a structural description, and the pathway the compound is studied in.
For an instrument-grade workflow this matters before any bench work starts. When a certificate of analysis lists a mass or a retention time, the researcher needs an independent expected value to compare it against. The library is one place to get that expected context. It does not replace the batch documentation supplied with a material. It gives the batch documentation something to be checked against.
What does the mechanism section show?
The mechanism section summarizes the pathway or target the compound is studied against, in prose, with the framing of published research models. For a small molecule this is usually an enzyme, a kinase or a nuclear receptor pathway rather than a cell-surface receptor.
Take AICAR as a worked example. It is a cell-permeable nucleotide analog studied for activation of AMP-activated protein kinase (AMPK). A library-style mechanism entry for it would describe the intracellular conversion to ZMP, the AMP-mimicking metabolite, and the AMPK-dependent readouts that research groups follow, such as phosphorylation of acetyl-CoA carboxylase in cell models. A researcher reading that entry learns which assay readouts are conventional for the compound, which is useful when designing a comparison between two AMPK-pathway tools.
Compare that with SLU-PP-332, a synthetic small molecule studied in connection with the estrogen-related receptor (ERR) family of nuclear receptors. The mechanism text for this one points to transcriptional regulation rather than kinase signaling. Reading the two entries side by side shows immediately that they are not interchangeable tools: one acts through a kinase cascade, the other through a nuclear receptor pathway. The library makes that difference visible in seconds.
What does the structure section show?
The structure section carries the identifiers a researcher cross-checks against analytical data: molecular formula, molecular weight and registry number where one exists. For the compounds in this brand's catalog, the values are:
SLU-PP-332: C20H18F3N3O2, 393.37 g/mol, CAS 2155854-26-3.
5-Amino-1MQ: C10H11N2 as the free-base form, 159.21 g/mol, CAS 42464-96-0.
Those figures come from this brand's own catalog records. When a library entry and a vendor record disagree, that disagreement is itself a finding. It may point to a salt form, a hydrate, or a typo in one of the sources. The right response is to check the primary documentation, not to assume either side is correct.
The molecular weight is particularly useful for mass-spectrometry work. A small molecule at 159 g/mol and one at 393 g/mol produce very different expected ions, and a library value lets a researcher set an expected m/z window before looking at a spectrum. For background on reading those spectra, see the brand's article on interpreting mass spec data.
What does the regulatory-status section show?
The regulatory-status section summarizes how the compound is categorized: whether it is an approved drug, an investigational compound, a research chemical, or a substance with restrictions in particular contexts. This is a different axis from mechanism and structure, and for small molecules it is often the least obvious one. Many metabolic-pathway tools began as clinical-stage or withdrawn candidates before circulating as research chemicals, and their category affects how institutions handle purchasing, storage records and disposal.
A researcher should read this section as a documentation prompt, not as a verdict. It indicates what paperwork an institution is likely to ask for. It does not replace the institution's own compliance review, and it makes no statement about suitability for any use outside controlled laboratory research.
How should the three sections be read together?
The useful habit is to read them as a triangle. Mechanism tells the researcher what the compound is for in an experimental design. Structure tells the researcher how to confirm that the material in hand is the compound named. Regulatory status tells the researcher what records need to exist around it.
A short checklist that follows from this:
Confirm the name and form against the structure entry before anything else.
Note the pathway in the mechanism entry and decide which readouts would actually distinguish it from a related tool.
Record the regulatory category in the project file next to the batch documentation.
Compare the library's expected identifiers with the batch's analytical data, and flag any mismatch for follow-up.
Applied to 5-Amino-1MQ, step two surfaces its framing as a small-molecule inhibitor studied against nicotinamide N-methyltransferase (NNMT) in cell-based metabolic models. That is a different enzyme class from the AMPK kinase studied with AICAR, so the two compounds call for different assay panels even though both appear under "metabolic research".
What are the limits of a compound library?
A library is a secondary source. Its entries summarize published work, and summaries lose detail. Three limits are worth stating plainly:
It is not batch documentation. Purity, identity and handling records belong to the specific lot, and only the lot's own certificate describes it.
It is not a substitute for primary literature. When an experimental design depends on a specific finding, read the original paper, including its methods and model system.
It reflects the state of the literature at the time of the entry. Fields move. A mechanism described as established in one year may be refined in the next.
Used within those limits, the library is a fast orientation tool. Used beyond them, it becomes a source of false confidence, which is a worse outcome than having no reference at all.
How does this connect to sourcing documentation?
Reading a library entry is the first half of a two-step check. The second half is reading the documentation that accompanies the material itself: the HPLC chromatogram, the mass-spectrometry identity data and the batch record. This brand's article on research compound sourcing documentation covers that second half in detail. The two together let a researcher say, with evidence, that the material matches the compound described and that the description matches the literature.
The other Amino Axiom surfaces, such as price comparison, the vendor directory, the compare tool and the glossary, are separate features of the same platform. This post covers only the compound library. Researchers who want to browse it directly can start from the Amino Axiom homepage or go straight to the compound library.
This article is provided for educational and research-information purposes only. The compounds discussed are research chemicals intended for laboratory research use only. They are not drugs, supplements, or food products, and are not intended to diagnose, treat, cure, or prevent any disease. Valitec Peptides does not supply products for human or animal use. Amino Axiom is an independent platform and this article makes no claims about its accuracy beyond what its entries visibly display.
